Catalyst Pharmaceuticals Appoints New Director
Ticker: CPRX · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, governance
Related Tickers: CPRX
TL;DR
Catalyst Pharma adds Dr. Peterson to the board, effective Jan 17.
AI Summary
Catalyst Pharmaceuticals, Inc. announced on January 17, 2025, a change in its board of directors. Specifically, Dr. Richard J. Peterson has been appointed as a new director, effective immediately. This appointment is part of the company's ongoing efforts to strengthen its governance and strategic oversight.
Why It Matters
The addition of a new director can bring fresh perspectives and expertise to the board, potentially influencing strategic decisions and company direction.
Risk Assessment
Risk Level: low — The filing concerns a routine board appointment, which typically carries low risk.
Key Players & Entities
- Catalyst Pharmaceuticals, Inc. (company) — Registrant
- Dr. Richard J. Peterson (person) — Newly appointed director
- January 17, 2025 (date) — Effective date of appointment
FAQ
Who is Dr. Richard J. Peterson and what is his background?
The filing does not provide specific details about Dr. Richard J. Peterson's background or qualifications, only that he has been appointed as a director.
What is the effective date of Dr. Peterson's appointment?
Dr. Richard J. Peterson's appointment as a director is effective January 17, 2025.
Are there any other changes to the board of directors mentioned in this filing?
This filing specifically details the appointment of Dr. Richard J. Peterson. It does not mention any other departures or appointments.
What is the primary business of Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals, Inc. is in the business of pharmaceutical preparations, as indicated by its SIC code [2834].
Where is Catalyst Pharmaceuticals, Inc. headquartered?
Catalyst Pharmaceuticals, Inc. is headquartered in Coral Gables, Florida, with its business address at 355 Alhambra Circle, Suite 801.
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-01-24 16:30:14
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
Filing Documents
- d911150d8k.htm (8-K) — 24KB
- 0001193125-25-012233.txt ( ) — 147KB
- cprx-20250117.xsd (EX-101.SCH) — 3KB
- cprx-20250117_lab.xml (EX-101.LAB) — 18KB
- cprx-20250117_pre.xml (EX-101.PRE) — 11KB
- d911150d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and CFO Dated: January 24, 2025 3